A Phase 2 Study of TH-4000 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Trial Profile

A Phase 2 Study of TH-4000 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Tarloxotinib (Primary)
  • Indications Head and neck cancer; Skin cancer; Squamous cell cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 29 Sep 2016 Status changed from recruiting to discontinued, considering the the totality of the clinical data obtained in the interim analysis which do not justify further evaluation, according to a Threshold Pharmaceuticals media release.
    • 29 Sep 2016 Interim results published in a Threshold Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top